Younger Generations: Key Drivers of the Global Blood Plasma Market in 2023 - Insights on Immunoglobulins, Coagulation Factors, and Albumin-derived Therapies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Blood Plasma Market: Analysis By Demand, By Production Capacity, By Type, By Industry, By Application, By Region, Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2028" report has been added to ResearchAndMarkets.com's offering.

The global blood plasma market in 2022 was valued at US$35.14 billion and is expected to reach US$56.55 billion by 2028, projected to grow at a CAGR of 8.25%, during the forecast period of 2023-2028.

In 2022, the global blood plasma market witnessed a supply of 54.75 million liters, while the global demand reached 72 million liters.

Blood plasma, the liquid component of blood, plays a vital role in the field of medicine. Comprising proteins, hormones, electrolytes, and antibodies, it serves as a crucial resource for various therapeutic applications. Blood plasma holds significant medical importance due to its use in treating a wide range of conditions.

Plasma-derived therapies, derived from blood plasma, have proven essential in the management of immune disorders, bleeding disorders, and rare diseases. Products such as immunoglobulins, coagulation factors, and albumin derived from plasma have saved countless lives and improved patients' quality of life.

The rise in prevalence of life-threatening disorders such as immunodeficiency, the rise in geriatric population, and growth in adoption of blood plasma derivatives products are expected to drive the blood plasma market. Moreover, advances in plasma fractionation technologies, increasing awareness of the benefits of plasma-derived therapies, and the potential for personalized medicine contribute to the sector's positive outlook.

Key players of the blood plasma market are:

• CSL Limited
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Baxter International Inc.
• Kedrion Biopharma
• ADMA Biologics, Inc.
• Octapharma
• LFB S.A.
• Taibang Biotech Group Inc. (China Biologic Products)

Market Dynamics

Growth Drivers

• Increasing demand for immunoglobulin in therapeutic treatments.
• Increasing plasma centers and plasma collection.
• Aging population.
• Rising prevalence of Alpha-1 Antitrypsin Deficiency (AATD).
• Rising incidence of hemophilia.

Challenges

• Availability of alternatives.
• Regulatory and safety considerations.

Market Trends

• Explosive growth of cell & gene therapies in development.
• Increasing adoption of therapeutic plasma exchange (TPE).
• Expansion of plasma fractionation facilities.

Market Segmentation Analysis:

• By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others. Immunoglobulin sector held the highest share in the market in 2022. Immunoglobulin products are derived from blood plasma and are used to treat various medical conditions, including immune deficiencies, autoimmune diseases, and certain infections. Immunoglobulin therapy is often required by older adults, as their immune systems tend to weaken with age. The expanding elderly population globally is driving the demand for immunoglobulin products. Moreover, advances in plasma fractionation techniques and the identification of new therapeutic uses for immunoglobulins have expanded the demand for these products. For example, immunoglobulins are increasingly being used in the treatment of neurological disorders like multiple sclerosis. However, there are still many patients undiagnosed, and consumption of immunoglobulins varies widely between regions, which suggests there is still room for further appealing growth.
• By Application: The global blood plasma market can be divided into four segments on the basis of application: Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia and Other. Hemophilia segment is anticipated to grow at the fastest CAGR during the forecasted period. Hemophilia is a genetic bleeding disorder characterized by a deficiency in clotting factors, primarily factor VIII (hemophilia A) or factor IX (hemophilia B). Plasma-derived clotting factor concentrates are a crucial treatment for hemophilia patients. Technological advancements in the production of clotting factor concentrates, along with improved clinical management of hemophilia, have increased the demand for plasma-based therapies. Furthermore, efforts to improve access to treatment in developing countries and initiatives to raise awareness about hemophilia have resulted in a higher number of patients seeking treatment, thereby driving the demand for plasma-derived product.
• By End User: The report divides the global blood plasma market into three end users: Hospitals, Clinics and Others. Hospitals are one of the major end users of blood plasma. They require blood plasma for various medical procedures, such as transfusions, surgeries, and treatments for patients with severe injuries or medical conditions. Patients with chronic diseases like hemophilia, immune deficiencies, and certain types of cancers may require regular blood plasma transfusions as a part of their treatment. The increasing prevalence of these diseases contributes to the demand for blood plasma in hospitals. With a globally aging population, the demand for blood plasma in hospitals is increasing.
• By Region: According to this report, the global blood plasma market can be divided into four major regions: North America (The US, Canada and Mexico), Europe (Germany, UK, France, Italy and Rest of Europe), Asia Pacific (China, Japan, India, and Rest of Asia Pacific), and Rest of the World. The North American region has emerged as a dominant player in the blood plasma market. The North American blood plasma market is a well-established and thriving industry. With advanced healthcare infrastructure and high healthcare expenditure, the region has witnessed significant growth in plasma-derived products.

For more information about this report visit https://www.researchandmarkets.com/r/ib1z18

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900